利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

25 条记录 (耗时 0.023 秒)

    COMBINATIONS COMPRISING EPOTHILONES AND PHARMACEUTICAL USES THEREOF
    21.
    发明申请
    COMBINATIONS COMPRISING EPOTHILONES AND PHARMACEUTICAL USES THEREOF 失效
    包含EPOTHILONES及其药物用途的组合

    公开(公告)号：US20080119529A1

    公开(公告)日：2008-05-22

    申请号：US12019294

    申请日：2008-01-24

    申请人： TianLing Chen ,  Diane Greeley ,  John Rothermel ,  Markus Wartmann ,  Jeanette Wood

    发明人： TianLing Chen ,  Diane Greeley ,  John Rothermel ,  Markus Wartmann ,  Jeanette Wood

    IPC分类号： A61K31/426 ,  A61P43/00 ,  C07D417/06

    CPC分类号： A61K31/663 ,  A61K31/427 ,  A61K31/502 ,  A61K31/555 ,  A61K33/24 ,  A61K45/06 ,  A61K2300/00

    摘要： The invention relates to a combination which comprises (a) a bisphosphonate, a platinum compound or a vasculostatic compound and (b) an epothilone derivative of formula I wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, and Z is O or a bond, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition, a commercial package or product comprising such a combination; the use of such a combination for the preparation of a medicament for the delay of progression or treatment of a proliferative disease and to a method of treatment of a warm-blooded animal.

    摘要翻译： 本发明涉及一种组合，其包含（a）二膦酸盐，铂化合物或血管平滑化合物和（b）式I的埃坡霉素衍生物，其中A表示O或NR N，其中R

    Epothilone resistant cell lines
    22.
    发明申请
    Epothilone resistant cell lines 审中-公开
    埃博霉素抗性细胞系

    公开(公告)号：US20070134744A1

    公开(公告)日：2007-06-14

    申请号：US11650375

    申请日：2007-01-05

    申请人： Peter Atadja ,  Markus Wartmann ,  Yan Yan-Neale ,  Dalia Cohen

    发明人： Peter Atadja ,  Markus Wartmann ,  Yan Yan-Neale ,  Dalia Cohen

    IPC分类号： G01N33/574 ,  C12N5/08 ,  A61K31/427

    CPC分类号： G01N33/5011 ,  A61K47/6803 ,  A61K47/6851 ,  C12N5/0693 ,  C12N2503/02 ,  G01N33/5008 ,  G01N33/5014

    摘要： Epothilone resistant cells lines are disclosed. The invention also discloses methods for identifying substances which are cytotoxic to epothilone resistant cells or which are chemosensitizers or analogs of epothilone. The invention further discloses methods for identifying epothilone resistant cells and for inhibiting the growth of epothilone resistant cells in vitro and in vivo. The invention also discloses antibodies specific for epothilone resistant cells. Also disclosed is a method to identify microtubule stabilizing agents using the epothilone resistant cell lines disclosed.

    摘要翻译： 披露埃坡霉素抗性细胞系。 本发明还公开了鉴定对埃坡霉素抗性细胞具有细胞毒性或是埃坡霉素的化学敏化剂或类似物的物质的方法。 本发明还公开了用于鉴定埃坡霉素抗性细胞并用于在体外和体内抑制埃坡霉素抗性细胞生长的方法。 本发明还公开了对埃坡霉素抗性细胞特异的抗体。 还公开了使用公开的埃坡霉素抗性细胞系鉴定微管稳定剂的方法。

    Tubulin Mutation Diagnostic
    23.
    发明申请
    Tubulin Mutation Diagnostic 审中-公开
    微管蛋白突变诊断

    公开(公告)号：US20100055709A1

    公开(公告)日：2010-03-04

    申请号：US12610400

    申请日：2009-11-02

    申请人： Kenneth Wayne Culver ,  Markus Wartmann ,  Stan Lilleberg ,  Jian Zhu

    发明人： Kenneth Wayne Culver ,  Markus Wartmann ,  Stan Lilleberg ,  Jian Zhu

    IPC分类号： C12Q1/68 ,  C07H21/04 ,  C07K14/435 ,  C12Q1/02

    CPC分类号： C12Q1/6883 ,  C07K14/47 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N33/5008 ,  G01N33/5011 ,  G01N33/68 ,  G01N33/6848 ,  G01N2800/52

    摘要： The present invention relates to methods for determining the potential of a subject to respond to a particular therapeutic agent, by determining the presence of one or more nucleotide or amino acid variants in the β-tubulin gene or protein. Also provided are methods for treating subjects whose potential to respond to a therapeutic agent has been evaluated. For use in the methods of the invention, there are provided variants of the β-tubulin gene. variants of the β-tubulin protein, nucleic acid molecules and agents which bind to the variant β-tubulin nucleic acid molecules and variant β-tubulin protein, respectively, and kits comprising the same.

    摘要翻译： 本发明涉及通过确定微管蛋白基因或蛋白质中一种或多种核苷酸或氨基酸变体的存在来确定受试者对特定治疗剂作出反应的潜力的方法。 还提供了用于治疗对治疗剂有响应的潜能的方法。 为了用于本发明的方法，提供了微管蛋白基因的变体。 分别结合变体和微管蛋白核酸分子和变体和微管蛋白的蛋白质的微管蛋白，核酸分子和试剂的变体和包含其的试剂盒。